Oragenics (NYSE:OGEN) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Oragenics (NYSE:OGEN) in a research note released on Tuesday morning. The firm issued a sell rating on the stock.

Oragenics Price Performance

OGEN opened at $1.15 on Tuesday. The business has a 50 day moving average of $1.98. Oragenics has a 1 year low of $1.02 and a 1 year high of $7.74. The firm has a market capitalization of $5.15 million, a PE ratio of -0.12 and a beta of 0.31.

Oragenics (NYSE:OGEN) last released its earnings results on Friday, March 29th. The company reported ($5.48) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Oragenics

Several hedge funds have recently modified their holdings of OGEN. Renaissance Technologies LLC boosted its position in shares of Oragenics by 116.5% in the second quarter. Renaissance Technologies LLC now owns 209,600 shares of the company’s stock worth $73,000 after acquiring an additional 112,800 shares during the last quarter. Millennium Management LLC lifted its position in Oragenics by 591.6% during the second quarter. Millennium Management LLC now owns 128,733 shares of the company’s stock valued at $45,000 after buying an additional 110,119 shares in the last quarter. Finally, State Street Corp lifted its position in Oragenics by 8.1% during the first quarter. State Street Corp now owns 495,563 shares of the company’s stock valued at $171,000 after buying an additional 37,338 shares in the last quarter. 18.71% of the stock is owned by institutional investors and hedge funds.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.